Verzenio (abemaciclib) Disease area(s): Oncology Manufacturer(s): Eli Lilly and Company 2024 Sales (USD): $5.31 billion Why it sold so well: In 2024, Eli Lillys treatment for HR-positive, HER2-negative breast cancer, Verzenio, experienced substantial sales growth, with global revenues increasing by 36% year-over-year to $1.56 billion in the fourth quarter, and $5.31 billion for the full year, an increase of 37% from the previous year
The guidelines mention that dietary supplements can be considered to mitigate nutrient, manage GI side effects, and preserve muscle mass
Several clinical trials have shown that consistent oral supplementation can, in fact, raise the levels of glutathione in the blood and within the cells themselves
[DOI] [PubMed] [Google Scholar] 39.Siniscalco D., Schultz S., Brigida A., Antonucci N